H.C. Wainwright Initiates Coverage on Mirna Therapeutics Inc to Buy

H.C. Wainwright Initiates Coverage on Mirna Therapeutics Inc(NASDAQ:MIRN). The shares have been rated Buy. The rating by H.C. Wainwright was issued on Sep 12, 2016.

In a different note, On Aug 17, 2016, Citigroup said it Maintains its rating on Mirna Therapeutics Inc. In the research note, the firm Lowers the price-target to $7.00 per share. The shares have been rated ‘Neutral’ by the firm. On Aug 16, 2016, Citigroup said it Downgrades its rating on Mirna Therapeutics Inc. In the research note, the firm Lowers the price-target to $7.00 per share. The shares have been rated ‘Neutral’ by the firm. On Aug 16, 2016, Oppenheimer said it Maintains its rating on Mirna Therapeutics Inc. In the research note, the firm Lowers the price-target to $13.00 per share. The shares have been rated ‘Outperform’ by the firm. On Aug 16, 2016, Leerink Swann said it Downgrades its rating on Mirna Therapeutics Inc. The shares have been rated ‘Market Perform’ by the firm.

Mirna Therapeutics Inc(MIRN) last announced its earnings results on Aug 15, 2016 for Fiscal Year 2016 and Q2.Earnings per share were $-0.27. Analysts had estimated an EPS of $-0.38.

Several Insider Transactions has been reported to the SEC. On Oct 7, 2015, Inc Pfizer (10% owner) purchased 714,285 shares at $7.00 per share price.Also, On Oct 6, 2015, Patrick J Kerins (10% owner) purchased 857,142 shares at $7.00 per share price.On Oct 6, 2015, Harry R Weller (10% owner) purchased 857,142 shares at $7.00 per share price, according to the Form-4 filing with the securities and exchange commission.

Mirna Therapeutics Inc. is a United States-based clinical-stage biopharmaceutical company. The Company is focused on developing a pipeline of microRNA (ribonucleic acid)-based oncology therapeutics. It is developing a cancer therapy microRNA Replacement Therapy focused on replacing naturally occurring microRNAs that are under expressed in cancer cells with microRNA mimics. Its pipeline of products includes MRX34 miR-101 miR-215 let-7 and miR-16. The Company’s lead product candidate MRX34 a mimic of naturally occurring microRNA-34 (miR-34) is in Phase I clinical trial in patients with primary liver cancer advanced solid tumors and hematological malignancies. Its miR-34 is considered a key regulator of multiple oncogenes across key oncogenic pathways. The Company focuses on developing MRX34 as a monotherapy and in combination with other therapeutic modalities such as targeted therapies and immuno-oncology agents.

Comments (0)

Leave a Reply

Your email address will not be published. Required fields are marked *

Mirna Therapeutics Inc - Is it time to Sell?

Top Brokerage Firms are advising their investors on Mirna Therapeutics Inc. Subscribe to MoneyFlowIndex.Org Pre-Market Alerts, You will be the first to know the street buzz.